KATHRINE LOHRFINK: Open Payments
NPI 1285996405 · CENTRAL POINT, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,571 in 10 payments from 6 companies in 2025. Trend: 2023 $326 · 2024 $453 · 2025 $2,571
Consulting: $2,300Food & beverage: $271
| Company | Payments | Amount |
|---|---|---|
| Eli Lilly and Company | 2 | $2,300 |
| Novo Nordisk Inc | 2 | $64 |
| Regeneron Healthcare Solutions, Inc. | 2 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $61 |
| Madrigal Pharmaceuticals | 2 | $54 |
| GlaxoSmithKline, LLC. | 1 | $30 |
Products named: ZEPBOUND, DUPIXENT, GLASSIA, REZDIFFRA, NUCALA, Rybelsus.
Industry payments across OR — which companies pay providers there.
